Insmed reported $468.87M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Cytokinetics USD 202.45M 60.31M Dec/2025
DBV Technologies USD 49.48M 60K Sep/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025